1   **A METHOD FOR PRODUCING A MULTI-GENE RECOMBINANT**

2   **VECTOR CONSTRUCT AND THE APPLICATION**

3   <u>BACKGROUND OF THE INVENTION</u>

4   1. Field of the Invention

5   The present invention is related to the biotechnology field, in particular a

6   method and vectors for producing multi-gene recombinant DNA and their

7   applications in biotechnology.

8   2. Description of Related Art

9   Genetic transformation is a basic technology in genetic engineering and

10   is used to introduce genes into cells of an organism. The majority of experiments

11   and applications performed to date involve the manipulation of a single or a few

12   genes. However, many important traits and complex metabolic pathways depend

13   upon interactions among a number of genes. Therefore, attempts have been

14   made to introduce multiple genes into cells of an organism to manipulate

15   polygenic traits and multiple traits, and produce multiple gene products.

16   However, genetic transformation with multiple genes is encumbered by

17   technical limitations of current technologies.

18   At present, the techniques used for introduction of multiple genes into

19   organisms include:

20   (1) co-transformation with mixed multiple plasmid vectors containing

21   different genes using particle bombardment and other methods (Chen *et al.*, 1998;

22   Ye *et al*, 2000);

23   (2) sequential re-transformation of the same recipient organism with

24   vectors where each vector contains one or a few genes (Lapierre *et al*, 1999); or

1 sexual crossing between transgenic organisms carrying different transgenes to

2 recombine the genes to a single organism (Ma and Hiatt, 1995); and

3   (3) linking of multiple genes of different sources into the same vector

4 using conventional molecular cloning technology for transformation (Van

5 Engelen *et al*, 1994; Daniell *et al*, 2001).

6   Although the first technique (1) is simple, the efficiency of co-

7 transformation with multiple plasmids decreases progressively with the increase

8 of the number of plasmids. Furthermore, co-transformation with separate

9 plasmids is a random event, thus the insertion copy numbers and the relative

10 arrangement among transgenes cannot be controlled. Therefore, some genes may

11 insert into the genome, and some genes may not.

12   For the second technique (2), the selectable marker for transformation

13 must be removed from the transgenic organisms, or a different selectable marker

14 must be used in each new round of transformation before the next round of

15 transformation. In addition, multiple rounds of transformation or cross between

16 transgenic organisms are very time-consuming, and hence this technique is

17 rarely used.

18   The third technique (3) is the most commonly used and reliable

19 approach. However, only a small number of genes can be cloned into a single

20 vector with the present molecular cloning technology (Halpin *et al.*, 2001) where

21 the introduction of multiple genes into a single vector is limited, for example, to

22 no more than four or five genes. This limitation has three main aspects. (1) When

23 sequentially combining multiple foreign DNA sequences into a vector, the size

24 of the recombinant vector will increase accordingly. Consequently, unique

1   cloning sites that usually are restriction endonuclease cutting sites will decrease,

2   and finally no suitable cloning sites will be available. (2) When the size of the

3   recombinant vector increases, the ligation efficiency between a new DNA

4   fragment and the vector decreases, especially for fragments with blunt ends. (3)

5   The cloning capacity of the conventional plasmid vectors (for example the pUC

6   vectors and its derivatives) is low so cloning of multiple genes using these

7   vectors is difficult. Although the cloning capacity of some vectors such as those

8   based on an F-factor or P1 replicon, e.g. bacterial artificial chromosomes (BAC,

9   P1), a binary bacterial artificial chromosome (BIBAC) and a transformation-

10   competent artificial chromosome (TAC), is larger than others (Sternberg *et al.*,

11   1990; Shizuya *et al.*, 1992; Halmilton, 1997; Liu *et al.*, 1999), the vectors with

12   large cloning capacities are only suitable for cloning a single large DNA

13   fragment but not for cloning multiple DNA fragments from different sources.

14   DNA recombination is defined as the exchange of DNA molecules

15   catalyzed by recombination enzymes (recombinases). DNA recombination

16   mediated by recombinase is a continuous process of cleavage, exchange and re-

17   ligation of DNA strands. Several DNA recombination systems, including

18   homologous recombination and site-specific recombination systems, have been

19   discovered. Recombination systems such as Cre/loxP, Rlp/FRT, R/Rs, attB/attP

20   and Gin/Gix systems enable recombination to occur between two specific

21   recombination sites and thus can be used for gene integration or gene removal

22   (Sternberg *et al*, 1981; Nash, 1981; Mcleld *et al*, 1986; Merker *et al*, 1993). For

23   example, the Cre recombinase catalyzes recombination between two plasmids to

24   produce a single recombinant (integrative) plasmid where each plasmid has a

1   loxP recombination site (34 base composed). Reverse recombination also occurs

2   between two loxP sites in directed-orientation in the integrative plasmid to

3   produce two separate plasmids. Although these recombination systems have

4   been successfully used in the recombination of target genes, current

5   methodologies only allow one or two rounds of recombination (McCormac *et*

6   *al.*,1999), and no effective methods are available for multiple rounds of gene

7   recombination to insert multiple genes into a single vector.

8   Accordingly, effective methods to insert multiple genes of interest into a

9   single vector are needed for manipulation of multiple genes for either applied or

10   academic purposes.

11   **SUMMARY OF THE INVENTION**

12   The present invention provides a method for effective assembly of

13   multiple genes or DNA fragments into single genetic engineering vectors and a

14   vector system employed for such purpose. The invention includes but is not

15   limited to: (i) a multi-gene assembly vector system comprising an acceptor

16   vector and at least two donor vectors; (ii) a method comprising a DNA

17   recombination system allowing multiple rounds of gene assembly by sequential

18   DNA delivery into an acceptor vector via DNA swapping between the acceptor

19   vector and different donor vectors; and (iii) specially designed DNA sequences

20   including cutting sites for rare-cutting endonucleases and irreversible

21   recombination sites on the acceptor and donor vectors for removing backbone

22   fragments of the donor vector from the integrative plasmid intermediate during

23   each round of recombination.

24   The method in accordance with the present invention allow the

4

1 manipulation of multiple genes in genetic engineering and the study of gene

2 functions including but not limited to transfer or expression of multiple genes

3 into recipients including but not limited to cells, tissues and organisms.

4 Examples are given in the present invention to demonstrate the capability and

5 effectiveness of the method to synthesize a single recombinant plasmid vector

6 carrying a large number of genes and DNA fragments, and of the subsequent

7 transfer of the linked genes and DNA fragments into the rice genome.

8 In the present invention, individual components including a DNA

9 recombination system, homing endonuclease cutting sites, the TAC and other

10 vector elements, which are currently used for other purposes, are compiled into a

11 new vector system to create a novel technology for link of multiple genes in a

12 single vector by multiple rounds of gene recombination. The present invention

13 overcomes the technical limitations experienced with existing methods for

14 synthesis of multi-gene vector constructs. The present invention is not limited by

15 the nature of the recombinase target site for recombination employed. In one

16 embodiment, the recombinase target site can be selected from the group

17 consisting of lox, FRT, Rs, att, Gix, or their mutant sites. The present invention is

18 not limited by the nature of the rare-cutting sites or irreversible recombination

19 sites employed either. In one embodiment, the sites can be selected from the

20 group consisting of homing endonuclease sites I-*Sce* I, I-*Ceu*I, I-*Ppo*I, I-*Tli*I,

21 PI-*Sce*I (*VDE*) or PI-*Psp*I or of irreversible specific recombination sites.

22 The benefits and advantages of the present invention are further

23 described with appropriate reference to the accompanying diagrammatic

24 exhibits.

BRIEF DESCRIPTION OF THE DRAWINGS

1   Figs. 1A-1C are schematic diagrams of a multi-gene assembly vector

2 system consisting of three plasmid vectors (**A**, **B** and **C**), where **A** is an acceptor

3 vector named pYLTAC747; **B** is a donor vector named pYLVS; and **C** is another

4 donor vector named pYLSV;

5   Fig. 2A is a schematic diagram depicting the first cycle of a gene

6 assembly process for recombination of a first gene (Gene 1) or an odd ordinal

7 gene;

8   Fig. 2B is a schematic diagram depicting the second cycle of the gene

9 assembly process for recombination of a second gene (Gene 2) or an even

10 ordinal gene;

11   Fig. 3 is a schematic diagram depicting the construction of the acceptor

12 vector pYLTAC747;

13   Fig. 4 is a schematic diagram depicting the construction of the donor

14 vectors pYLVS and pYLSV;

15   Fig. 5 is an electrophoresis diagram of multi-gene constructs containing

16 different numbers of genes in the acceptor vector pYLTAC747, which were

17 digested by a restriction endonuclease *NotI*;

18   Fig. 6 is a schematic diagram of a multi-gene construct pYLTAC747-

19 10G in which 10 genes or DNA segments were stacked; and

20   Fig. 7 is a photographic diagram of the Southern hybridization detection

21 of multiple genes in transgenic rice plants transformed with the multi-gene

22 vector construct pYLTAC747-10G.

DETAILED DESCRIPTION OF THE INVENTION

1   Theoretically, genes carried on separate donor and acceptor vectors can

2   be linked together in an integrative vector indefinitely by multiple rounds of

3   co-integration events using a recombination system. The donor vectors and

4   acceptor vectors each comprises a backbone sequence contained a

5   recombination site, an origin sequence for replication and a bacterial selection

6   marker. However, the backbone sequence of the donor vector must be removed

7   from the integrative vector prior to subsequent round of vector recombination

8   after the first round of recombination. This backbone removal is necessitated

9   because: (i) the doubled replication origins cause instability of the integrative

10   vector in bacteria, and the direct-repeated recombination sites result in reverse

11   recombination; and (ii) a new selection marker gene will be needed in each

12   subsequent round of recombination if the marker gene on the donor vector is not

13   deleted from the integrative vector.

14   Therefore, two important technical issues must be resolved for multiple

15   cycles of gene recombination. Specifically, (i) appropriately positioned cutting

16   sites in the vectors must be available for the backbone removal in each round of

17   gene recombination; and (ii) the cutting sites for removing the donor backbone

18   must not occur elsewhere within the backbone of the acceptor vector and its

19   growing inserted genes. However, if the cutting sites are not destroyed after each

20   recombination round, the same kinds of sites cannot be used in the subsequent

21   rounds of recombination. When the number of recombined genes increases, the

22   availability of suitable cutting sites decreases.

23   Endonuclease for genetic engineering with low frequency of recognition

24   sites in genomes is usually called "rare-cutting" endonuclease. Among those,

7

1   homing endonucleases or meganuclease, such as I-*Sce*I, I-*Ceu*I, I-*Ppo*I, I-*Tli*I,

2   PI-*Sce*I (VDE) and PI-*Psp*I, are very-rare-cutting enzymes. The recognition

3   sequences of homing endonucleases have the following characteristics. (i) The

4   recognition sequences are much longer in bases than those of restriction

5   endonucleases. For example I-*Sce*I and PI-*Sce*I recognize 18-base-pair and 39-

6   base-pair sites, respectively; so the theoretical cutting frequency of natural DNA

7   sequences by the enzymes is very low. (ii) The recognition sequences are

8   asymmetric (Belfort & Roberts, 1997). When two reverse-directed cutting sites

9   are digested by a homing endonuclease and the two ends are subsequently

10   ligated, the joining site no longer contains a complete recognition sequence of

11   the endonuclease.

12   Some recombination reactions of most recombination systems are

13   reversible. However, some reversible site-specific recombination systems may

14   be modified to produce irreversible recombination (Albert *et al.*, 1997), like that

15   of the *att*B/*att*P system mediated by lambda integrase. Irreversible

16   recombination can be used to remove irreversible DNA fragments between two

17   recombination sites, and the two ends can be combined at the same time.

18   To address the foregoing issues raised above, the present invention

19   provides a method and a multi-gene assembly vector system for effective

20   assembly of multiple genes into a single vector. The vector system consists of an

21   acceptor vector and at least two donor vectors. The method comprises a DNA

22   recombination system allowing multiple rounds of gene recombination by

23   sequential DNA delivery into the acceptor vector via DNA swapping between

24   the acceptor vector and different donor vectors. Multiple donor vectors will be

1   rotatively used in different rounds of recombination to allow sequential insertion

2   of genes or DNA fragments into the acceptor vector.

3   During the plasmid recombination rounds, specially designed DNA

4   sequences including cutting sites for rare-cutting endonucleases or irreversible

5   recombination sites on the acceptor and donor vectors allow removal of the

6   backbone fragments of the donor vector from the integrative plasmid

7   intermediate in each round of recombination. The method allows continual

8   cycling of gene recombination until all target genes or DNA fragments

9   subcloned in the donor vectors are delivered into the acceptor vector.

10   In a preferred embodiment of the method, the vectors described in the

11   present invention have two kinds of homing endonucleases cutting sites for the

12   removal of unwanted donor vector backbone fragments, so that cutting of the

13   combined genes or the acceptor vector is avoided. A similar effect can also be

14   achieved using recognition sites for other rare-cutting endonucleases or

15   irreversible recombination sites. By alternate use of the two donor vectors, just

16   two kinds of endonuclease cutting sites or irreversible recombination sites are

17   enough for the multiple rounds of the gene recombination.

18   The acceptor vector according to the present invention is a recipient of

19   foreign genes or DNA fragments to be delivered, which is characterized by

20   (1) having a site RS for DNA recombination and can be but is not limited

21   to loxP, FRT, Rs, attB, attP, or Gix;

22   (2) having a site S1 located near the site RS and is a cutting site for a

23   homing endonuclease or a restriction endonuclease or a site for irreversible

24   recombination;

1   (3) having a selection marker gene, which can be but is not limited to be

2   an antibiotic resistance gene; and

3   (4) that a replican for replication is capable of maintaining a large

4   plasmid, which can be but is not limited to bacteriophage P1 replicon, F-factor

5   replicon, Ri replicon, or pVS1 replicon.

6   The donor vectors in accordance with the present invention are

7   intermediate vectors for transfer of genes of interest to the acceptor vector

8   through gene recombination. The two donor vectors are a donor vector named

9   donor vector I and another donor vector named donor vector II, and are

10   characterized by:

11   (1) having a site RS for DNA recombination which is the same site RS as

12   in the acceptor vector or can form a recombination with the RS in the acceptor

13   vector;

14   (2) having a site S1 and another site S2, which are cutting sites for

15   homing endonucleases, rare-cutting restriction endonucleases or irreversible

16   recombination;

17   (3) that the sites RS, S1, S2 and multi-cloning site (MCS) are located on

18   donor vector I in a relative order of RS-S2-MCS-S1, and on donor vector II in a

19   relative order of RS-S1-MCS-S2.

20   (4) that the donor vector I and donor vector II each has a selection

21   marker gene, which is different from that in the acceptor vector, and can be but is

22   not limited to be an antibiotic resistance gene and can be the same or different in

23   the donor vectors.

24   The foregoing homing endonuclease sites can be but are not limited to

1   I-*Sce* I, I-*Ceu*I, I-*Ppo*I, I-*Tli*I, PI-*Sce*I (VDE) or PI-*Psp*I.

2   The foregoing irreversible specific recombination sites can be but are

3   not limited to attB, attP, modified attB, modified attP, modified loxP, modified

4   FRT, modified Rs or modified Gix.

5   With reference to Fig.1, an example of a multi-gene assembly vector

6   system in accordance with the present invention includes three vectors (A, B and

7   C). Vector A is an acceptor vector named pYLTAC747, vector B is donor vector I

8   named pYLVS, and vector C is donor vector II named pYSV. In the three vectors

9   (A, B and C), the site RS is represented by loxP, the site S1 by I-*Sce*I, the site S2

10   by PI-*Sce*I, and MCS is a multi-cloning site consisting of 23 unique restriction

11   endonuclease cutting sites for cloning foreign genes. In the donor vectors (B, C),

12   LacZ is a galactosidase gene as a selection marker for cloning, and Cm is a

13   chloramphenicol-resistance selection marker gene. In the acceptor vector (A),

14   Kan is a kanamycin-resistance selection marker gene. RB and LB are

15   respectively the right and left borders of the transfer DNA region (T-DNA). The

16   P1 plasmid replicon in the acceptor vector (A) is originally taken from the

17   bacteriophage P1, which makes the plasmid replicate in *E. coli*. The Ri replicon

18   in the acceptor vector (A) is originally taken from *Agrobacterium rhizogenes* Ri

19   plasmid and makes the plasmid replicate in *Agrobacterium rhizogenes* and

20   *Agrobacterium tumefaciens*. Ori in the donor vectors (B, C) is a pUC plasmid

21   replication origin.

22   The method to assembly multiple genes in accordance with the present

23   invention comprises the steps of (1) cloning target genes or DNA fragments into

24   separate donor vectors, (2) performing plasmid recombination of donor vector I

1 and the acceptor vector, (3) performing plasmid recombination of donor vector II

2 and the acceptor vector and (4) repeating the second and third steps until all

3 desired target genes and DNA fragments are transferred to the acceptor vector.

4 Target genes or DNA fragments are cloned by conventional cloning

5 techniques into the MCS of separate donor vectors to make the genes inserted

6 between the sites S1 and S2, in the order the genes are to be combined in the

7 acceptor vector. If technically possible, two or more genes may be cloned as a

8 gene group into a donor vector. The word "gene" as used in the detailed

9 description represents either a functional gene or a DNA fragment.

10 With reference to Fig.2A, the donor vector I plasmid containing the first

11 gene or gene group (pYLVS-Gene 1) and acceptor vector plasmid pYLTAC747

12 are co-transferred into an *Escherichia coli* (*E. coli*) host that expresses the Cre

13 recombinase which catalyzes the plasmid recombination *in vivo*. The

14 transformants are then selected on selection medium containing kanamycin and

15 chloramphenicol. The plasmids consisting of integrated and separate plasmids

16 are purified, and then re-transferred into an *E. coli* host that does not have the *Cre*

17 gene, and the transformants are selected on selection medium containing

18 kanamycin and chloramphenicol. The plasmid recombination also can be carried

19 out *in vitro* with purified Cre recombinase. A backbone fragment of pYLVS

20 flanked by the two I-*Sce*I sites is removed by digestion with endonuclease I-*Sce*I.

21 Since the two asymmetric I-*Sce*I sites on the co-integrated plasmid are arranged

22 in opposite orientation, the protruding 3' ends are not complementary to each

23 other, and the plasmid circularization by T4 DNA ligase reaction formed a

24 joining site requires the aid of a compatible double-stranded oligo-nucleotide

1   linker S. The resulting joining site on the plasmid is no longer recognized by the

2   enzyme during subsequent gene-assembly cycles. The resulted plasmid bearing

3   Gene 1 is transferred into *E. coli*. Transformants are selected on selection

4   medium containing kanamycin, and then tested for chloramphenicol-sensitivity.

5   The selected clone is a new plasmid without the pYLVS backbone fragment but

6   with Gene1 inserted, which is named pYLTAC747-Gene 1. On pYLTAC747-

7   Gene 1, the homing endonuclease cutting site is replaced by a PI-*Sce*I site that is

8   derived from pYLVS.

9   With reference to Fig.2B, the donor vector II plasmid containing the

10   second gene or gene group (pYLSV-Gene 2) and the acceptor vector plasmid

11   pYLTAC747-Gene 1 are co-transferred into an *E. coli* host that expresses the Cre

12   recombinase. Transformants are selected on selection medium containing

13   kanamycin and chloramphenicol. The plasmids are purified, re-transferred into

14   an *E. coli* host that does not have the *Cre* gene and selected on selection medium

15   containing kanamycin and chloramphenicol. The plasmid recombination also

16   can be carried out *in vitro* with purified Cre recombinase. A backbone fragment

17   of pYLSV flanked by the two PI-*Sce*I sites is removed by digestion with

18   endonuclease PI-*Sce*I. Since the two asymmetric PI-*Sce*I sites on the co-

19   integrated plasmid are arranged in opposite orientation, the protruding 3' ends

20   are not complementary to each other, and the plasmid circularization by ligation

21   formed a joining site requires the aid of a compatible double-stranded linker V.

22   After ligation with T4 DNA ligase, the resulting joining site on the plasmid is no

23   longer recognized by the enzyme during subsequent gene-assembly cycles. The

24   resulted plasmid bearing Gene 1 and Gene 2 is transferred into *E. coli*.

1   Transformants are selected on selection medium containing kanamycin and then

2   tested with chloramphenicol for chloramphenicol-sensitivity. The selected clone

3   is a new plasmid without the pYLSV backbone fragment but with Gene 2, which

4   is named pYLTAC747-Gene1-Gene2. The cutting site for homing endonuclease

5   on this new plasmid becomes I-*SceI*, the same as that on the original vector

6   pYLTAC747.

7   The second and third steps described above are repeated alternately with

8   the donor vectors I and II containing new target genes for the gene recombination

9   until all target genes are delivered into the acceptor vector.

10   The I-*SceI* recognition sequence and cutting point (arrowed) are as

11   follows:

12   5'-TAGGGATAA↓CAGGGTAAT-3'

13   3'-ATCC↑CTATTGTCCCATTA-5'

14   Two reverse-directed I-*SceI* cutting ends and an oligo-nucleotide linker

15   S (presented by lowercase letters) are combined to produce a joining site as

16   follows:

17   5'-TAGGGATAAnnn···nnnttatCCCTA-3'

18   3'-ATCCCtattnnn···nnnAATAGGGAT-5'

19   The base number of the linker core sequence (n) is preferably eight or

20   more, and the linker core sequence (n) can be any bases but cannot form a

21   complete I-*SceI* or PI-*SceI* recognition site. In an example (Fig. 5 and Fig.6) of

22   the present invention, a restriction site *NotI* is designed in the linker S:

23   5'-**gcggccgc**ttat-3'

24   3'-tatt**cgccggcg**-5'

14

1   The PI-*Sce*I recognition sequence and cutting point (arrowed) are as

2   follows:

3   5'-ATCTATGTCGGGTGC↓GGAGAAAGAGGTAATGAAATGGCA-

4   3'

5   3'-TAGATACAGCC↑CACGCCTCTTTCTCCATTACTTTACCGT-5'

6   Two reverse-directed PI-*Sce*I cutting ends and an oligo-nucleotide linker

7   V (presented by lowercase letters) are combined to produce a joining site as

8   follows:

9   5'-ATCTATGTCGGGTGCnnn···nnngcacCCGACATAGAT-3'

10   3'-TAGATACAGCCcacgnnn···nnnCGTGGGCTGTATCTA-5'

11   The base number of the linker core sequence (n) is preferably eight or

12   more, and the linker core sequence (n) can be any bases but cannot form a

13   complete PI-*Sce*I or I-*Sce*I recognition site. In an example (Fig. 5 and Fig.6) of

14   the present invention, a restriction site *Not*I is designed in the linker V:

15   5'-gcggccgcgcac-3'

16   3'-cagccgccggcg-5'

17   Accordingly, a method for producing a recombinant vector construct in

18   accordance with the present invention comprises providing an acceptor vector

19   and a donor vector, introducing the acceptor vector and the donor vector into

20   cells allowing occurrence of DNA recombination, subjecting the cells to drug

21   selection, obtaining a recombinant vector, subjecting the recombinant vector to

22   endonuclease digestion and drug selection and obtaining a recombinant acceptor

23   vector.

24   The acceptor vector provided comprises a sequence for DNA

1   recombination or called DNA recombination sequence, a selection marker gene

2   and a first endonuclease cutting site. The first endonuclease cutting site is

3   flanked by the sequence for DNA recombination and is unique in the acceptor

4   vector. The selection marker gene is flanked by the first endonuclease cutting

5   site.

6   The donor vector provided comprises a DNA recombination sequence, a

7   target sequence of interest to be delivered into the acceptor vector, a selection

8   marker gene, a first endonuclease cutting site and a second endonuclease cutting

9   site. The first endonuclease cutting site and the second endonuclease cutting site

10 are each unique in the donor vector. The DNA recombination sequence can form

11 a recombination with the corresponding sequence in the acceptor vector. The

12 DNA recombination sequence is flanked by the second endonuclease cutting site.

13 The target sequence of interest is flanked by the second endonuclease cutting site

14 and the first endonuclease cutting site. The selection marker gene is flanked by

15 the first endonuclease cutting site and is different from the selection marker gene

16 in the acceptor vector.

17   The acceptor vector and the donor vector are introduced into cells to

18 allow plasmid recombination between the acceptor vector and the donor vector

19 carrying the target sequence. The cells are subjected to drug selection with

20 respect to the two different selection marker genes in the acceptor vector and the

21 donor vector, respectively. A recombinant vector is obtained from the cells

22 surviving from the drug selection. The recombinant vector is subjected to

23 endonuclease digestion with the first endonuclease followed by self-ligation to

24 form a circular recombinant plasmid. The recombinant plasmid is subjected to

1   drug selection with the selection marker gene in the acceptor vector. A

2   recombinant acceptor vector surviving from the drug selection is obtained. The

3   recombinant acceptor vector comprises the target sequence of interest from the

4   donor vector, the second endonuclease cutting site, the selection marker gene in

5   the acceptor vector and the DNA recombination sequence.

6   Preferably, the method for producing a multi-gene recombinant vector

7   construct further comprises repeating one or more times the steps of providing an

8   additional donor vector carrying a target sequence of interest, introducing the

9   recombinant acceptor vector and the additional donor vector into cells to allow

10 DNA recombination, subjecting the cells to drug selection, obtain a recombinant

11 vector, subjecting the recombinant vector to endonuclease digestion and self-

12 ligation, and drug selection and obtaining a new recombinant acceptor vector.

13   The additional donor vector provided comprises a DNA recombination

14 sequence, a target sequence of interest to be delivered into the acceptor vector, a

15 selection marker gene, a first endonuclease cutting site and a second

16 endonuclease cutting site. The first endonuclease cutting site and the second

17 endonuclease cutting site are each unique in the donor vector. The DNA

18 recombination sequence can form a recombination with the corresponding

19 sequence in the acceptor vector. The DNA recombination sequence is flanked by

20 the first endonuclease cutting site. The target sequence of interest is flanked by

21 the first endonuclease cutting site and the second endonuclease cutting site. The

22 selection marker gene is flanked by the second endonuclease cutting site and is

23 different from the selection marker gene in the acceptor vector.

24   The recombinant acceptor vector and the additional donor vector are

1   introduced into cells to allow occurrence of plasmid recombination between the

2   acceptor vector and the donor vector carrying the target sequence. The cells are

3   subjected to drug selection with respect to the two different selection marker

4   genes in the recombinant acceptor and the additional donor vector, respectively.

5   A recombinant vector is obtained from the cells surviving from the drug

6   selection. The recombinant vector is subjected to endonuclease digestion with

7   the a endonuclease that cut the same endonuclease cutting site in the

8   recombinant acceptor vector, followed by self-ligation to form a circular

9   recombinant plasmid. A recombinant acceptor vector surviving the drug

10 selection is obtained. The recombinant acceptor vector comprises the target

11 sequence of interest in the additional donor vector.

12   The acceptor vector may comprise all or part of DNA sequence SEQ ID

13 NO: 1 (see below). The first donor vector may comprise all or part of DNA

14 sequence SEQ ID NO: 2 (see below). The second donor vector may comprise all

15 or part of DNA sequence SEQ ID NO: 3 (see below).

16   Other possible modifications and variations can be made without

17 departing from the spirit and scope of the present invention as claimed in the

18 invention. Such modifications may concern but are not limited to the number of

19 donor vectors or the number and/or arrangements of the specific sites for

20 recombination and digestion. For example, three or more donor vectors can be

21 used in turn to recombine with the acceptor vector. In the case of using three

22 donor vectors, the sites and their location orders on the acceptor vector and the

23 donor vectors can be designed as follows:

24   acceptor vector: RS-S1

18

1   donor vector I: RS-S2-MCS-S1

2   donor vector II: RS-S3-MCS-S2

3   donor vector III: RS-S1-MCS-S3

4   Herein RS is a recombination site. S1, S2 and S3 are cutting sites for

5   homing endonucleases or rare-cutting endonucleases or irreversible

6   recombination sites. During multi-gene assembly cycling, each donor vector is

7   used in turn in the order of donor vector I, donor vector II, donor vector III, donor

8   vector I, donor vector II and so on.

9   The multi-gene assembly method in accordance with the present

10   invention has several applications. The present invention can preferably be used

11   to construct multi-gene transformation vectors suitable for various

12   transformation methods, so that multiple genes can be transferred together into

13   various recipient organisms including but not limited to plants, animals, insects,

14   yeast and micro-organisms, for the purposes of production of multiple gene-

15   products or expression of characters based on interactions of multiple genes.

16   Transformation methods for transfer of multiple genes with constructs made

17   according to the present invention comprises but are not limited to the

18   *Agrobacterium*-mediated transformation method, particle bombardment, micro-

19   injection, electroporation, Polyethylene Glycol method, pollen-tube pathway

20   transformation method or viral mediated gene transformation method. For

21   example, the acceptor vector pYLTAC747 described in the present invention as

22   an example contains all components of a binary transformation vector needed for

23   *Agrobacterium*-mediated transformation, i.e., the right and left borders of a T-

24   DNA region, the bacteria antibiotic selection marker (kanamycin-resistance gene)

19

1   and the P1 and Ri plasmid replicons functional in *E. coli* and *Agrobacterium*.

2   After insertion of a plant selection marker gene and other target genes into

3   pYLTAC747 with the method of the present invention, the vector constructs can

4   be used for transformation of plants by *Agrobacterium*-mediated transformation

5   or other transformation methods. Using the method in accordance with the

6   present invention, various types of vectors can be modified easily as the acceptor

7   and donor vectors suitable for assembly of multiple genes or DNA fragments to

8   construct various types of genetic engineering vectors for specific purposes,

9   especially large-size or intricate vectors containing multiple elements, for

10 example bacterial artificial chromosomes, yeast artificial chromosomes,

11 mammalian artificial chromosomes or plant artificial chromosomes.

12   The present invention has the following advantages:

13   The method is flexible and versatile. Multiple genes or DNA fragments

14 of different sources can be effectively combined into one vector, and the

15 placement and orientation of target genes in the vector can be freely designed

16 and readily achieved in a reliable step-by-step process. The present invention

17 overcomes the technical limitations of existing cloning methods for producing

18 multi-gene vector constructs.

19   By alternately using two donor vectors with an acceptor vector for gene

20 recombination, multiple cycles of gene recombination can be repeated. With this

21 strategy, just two rare-cutting sites for endonuclease or irreversible specific

22 recombination sites are enough to remove the unneeded backbone fragments of

23 the donor vectors, which is a necessary step for multiple rounds of gene

24 recombination.

20

1   Using replicons with the ability to maintain a large plasmid, such as the

2   P1 plasmid replicon and the Ri replicon, the acceptor vector described in the

3   present invention can accept and stably maintain a large number of foreign

4   genes.

5   All of the documents or publications recited in the text are incorporated

6   herein for reference.

7   **EXAMPLES**

8   The present invention is further described in specific detail by reference

9   to the following examples showing construction of the multi-gene assembly

10   vector system and its application to introduce multiple genes into rice. However,

11   the claims of the present invention are not limited by these examples.

12   **Example 1**

13   This example shows the construction of the acceptor vector

14   pYLTAC747.

15   With reference to Fig. 3, Primer P1 is:

16   5'-CTCATG<u>TCTAGA</u>TTGTCGTTTCCCGCCTTCAGT-3', the

17   underlined sequence is a *Xha*I restriction site.

18   Primer P2 is:

19   5'-

20   ACC<u>GGATCC</u>T*GTTTACACCACAATATATCCTGCC*ACGTTAAAGACTTCAT

21   -3', the underlined sequence is a *Bam*HI restriction site, and the italicized

22   sequence is the left border LB of T-DNA.

23   The fragment MCS—loxP—I-*Sce*I fragment (SEQ ID NO: 1) is: 5'-

24   <u>GGATCCAAGCTTGTCGACGGCCGGCCGCGGCCGC</u>*ATAACTTCGTATAG*

1 *CATACATTATACGAAGTTAT*GGGCCGCattaccctgttatccctaGGCCCCAATTAG

2 GCCTACCCACTAG-3'. The underlined sequence is the multiple cloning site

3 (MCS) composed of *Bam*HI, *Hind*III, *Fse*I and *Not*I. The italicized sequence is

4 the LoxP site. The lowercase letters are an I-*Sce*I site.

5   The primers P1 and P2 containing *Xba*I and *Bam*HI sites were

6 synthesized according the transformation-competent artificial chromosome

7 vector pYLTAC7 sequence (Liu et al., 1999). A vector frame fragment (15690 bp)

8 was amplified by PCR and digested with *Xba*I and *Bam*HI and ligated with the

9 synthesized double-stranded DNA fragment MCS—loxP—I-SceI (SEQ ID

10 NO:1) to produce an acceptor vector plasmid, which was named pYLTAC747.

11 **Example 2**

12   This example shows the constructionof the donor vectors.

13   With reference to Fig. 4, pCAMBIA1200 and pBluescript SK were

14 plasmid vectors. Ori is a plasmid replication origin. Cm is a chloramphenicol-

15 resistance gene. Amp is an ampicillin-resistance gene. LacZ is a galactosidase

16 gene as a selection marker.

17   Primer 3 is 5'-CTTCAATATTACGCAGCA-3'

18   Primer 4 is 5'-GAGCAATATTGTGCTTAG-3'

19   Primer 5 is 5'-GTTCTCGCGGTATCATTG-3'

20   Primer 6 is 5'-CCATTCGCCATTCAGGCTG-3'

21   The sequence loxP—PI-*Sce*I—MCS—I-*Sce*I region in the donor vector

22 I plasmid pYLVS (SEQ ID NO: 2) is: 5'-

23 GCGCGCTC*ATAACTTCGTATAGCATAC*

24 *ATTATACGAAGTTAT*CAGATCTTTTTGGCTACCTTAAG<u>TGCCATT</u>

1   <u>TCATTACCTCTTTCTCCGCACCCGACATAGAT</u>GTTAAGAGAGTCATAT

2   CGATGCATGCGGCCGCTAGCTCGAGCTCTAGAATTCTGCAGGTACCG

3   CGGATCCATGGGCCCGGGACTAGTCGACATGTACAAGCTTGtagggataaa

4   cagggtaatCCCTAAGATCTCAGCGCGC-3'

5   The sequence loxP—I-*SceI*—MCS—PI-*SceI* in the donor vector II

6   plasmid pYLSV (SEQ ID NO: 3) is: 5'-

7   GCGCGCTC*ATAACTTCGTATAGCATACATTATACGAAGTTAT*CAGATCTTA

8   GGGattaccctgttatccctaCAAGCTTGTACATGTCGACTAGTCCCGGGCCCAT

9   GGATCCGCGGTACCTGCAGAATTCTAGAGCTCGAGCTAGCGGCCGCA

10   TGCATCGATATGACTCTCTTAAC<u>ATCTATGTCGGGTGCGGAGAAAGAG

11   GTAATGAAATGGCAC</u>TTAAGGTAGCCAAAAAGATCTCAGCGCGC-3'

12   The italicized sequence is a loxP site. The underlined sequence is a PI-

13   *SceI* site. The lowercase sequence is an I-*SceI* site. The sequence between the PI-

14   *SceI* site and the I-*SceI* site is a multi-cloning site (MCS) consisting of 23 unique

15   restriction sites.

16   The primers P3 and P4 were synthesized based on the sequence of the

17   chloramphenicol-resistance gene. A chloramphenicol-resistance gene Cm (826

18   bp) was amplified by PCR from plasmid pCAMBIA1200. The primers P5 and

19   P6 were synthesized based the plasmid pBluescript SK sequence, and a fragment

20   (Ori—MCS—LacZ) of 1660 bp was amplified by PCR from the plasmid

21   pBluescript SK. The two fragments were ligated and transferred to *E. coli*

22   DH10B to obtain an intermediate plasmid pYL. The original MCS in plasmid

23   pYL that was derived from pBluescript SK was removed by digestion with

24   restriction endonuclease *Bss*HII, and the synthesized double-stranded DNA

1   fragment loxP—PI-*Sce*I—MCS—I-*Sce*I (SEQ ID NO: 2) was inserted into the

2   plasmid by ligation to form a new plasmid. This plasmid was donor vector I and

3   was named pYLVS. Two restriction sites *Bgl*II were designed on the vector, one

4   located between loxP and PI-*Sce*I, and the other located between I-*Sce*I and LacZ.

5   Therefore another donor vector (donor vector II) was produced from pYLSV by

6   digestion with *Bgl*II and re-ligation to insert the *Bgl*II-fragment containing the

7   I-*Sce*I—MCS—PI-*Sce*I sites back into the vector in the opposite orientation. In

8   donor vector II, the relative locations of the sites were changed to LoxP—I-

9   *Sce*I—MCS—PI-*Sce*I (SEQ ID NO: 3), and this vector was named pYLSV.

10   **Example 3**

11   This example illustrates the construction of vector constructs containing

12   multiple genes for plant transformation.

13   With reference to Fig. 5, multiple vector constructs containing different

14   number genes were digested with a restriction endonuclease *Not*I and subjected

15   to gel electrophoresis. The figures at the bottom of Fig. 5 indicated the number of

16   target genes and functional DNA fragment delivered into the vector pYLTAC747

17   during the following multi-gene assembly process. The 5.2 kb band in lanes 7-10,

18   1.2 kb band in lanes 9-10 and 3.0 kb band of lane 10 are bands with two co-

19   migrating fragments (see Fig. 6 for the sizes of the *Not* I fragments). Lane M is a

20   lambda DNA/*Hind*III molecular weight marker.

21   Genes and functional DNA sequences used for the recombination were

22   hygromycin-resistance gene (HPT), matrix attachment region (MAR), snow

23   drop lectin gene (Galanthus nivalis agglutinin) (GNA), potato proteinase

24   inhibitor II (PinII), rice acidic chitinase (RAC22), rice basic chitinase (RCH10),

1   rice bacterial blight resistance gene (Xa21), and beta-glucuronidase gene (GUS).

2   These genes were originally individually cloned in plasmid vector pBluescript

3   SK+ or pUC18.

4   The first gene HPT was directly cloned into the *Not*I site of pYLTAC747

5   by conventional cloning methods. The produced vector pYLTAC747-HPT was

6   presented in Fig. 5 lane 2.

7   The MAR sequence (1.2 kb) was sub-cloned into the donor vector I

8   plasmid pYLVS to produce pYLVS-MAR. The pYLVS-MAR and

9   pYLTAC747-HPT were used to co-transform *E. coli* NS3529 that contains the

10   Cre gene and expressed Cre recombinase, and formed a recombined plasmid.

11   The recombined plasmid was selected on an LB medium containing kanamycin

12   and chloramphenicol, purified and re-transferred to *E. coli* DH10B lacking the

13   Cre gene. The integrated plasmid was subjected to I-*Sce*I digestion to cut off the

14   pYLVS backbone. The digested plasmid was ligated with an oligo-nucleotide

15   linker S (containing a *Not*I site) with T4 DNA ligase to form a circular plasmid.

16   After testing for chloramphenicol-sensitivity, a new plasmid named

17   pYLTAC747HPT-MAR was obtained (Fig. 5 lane 3).

18   The GNA gene (5.2 kb) was subcloned into the donor vector II pYLSV

19   to produce pYLSV-GNA. The pYLSV-GNA and pYLTAC747-HPT-MAR were

20   used to co-transform NS3529 to form a recombined plasmid. The recombined

21   plasmid was selected on LB medium containing kanamycin and

22   chloramphenicol, purified and re-transferred to DH10B. The integrated plasmid

23   was purified and subjected to PI-*Sce*I digestion to cut off the pYLSV backbone.

24   The digested plasmid was ligated with an oligo-nucleotide linker V (containing a

1   *Not*I site) with T4 DNA ligase to form a circular plasmid. After testing for

2   chloramphenicol- sensitivity, a new plasmid named pYLTAC747HPT-MAR-

3   GNA was obtained (Fig. 5 lane 4).

4   The PinII gene (3.0 kb) was subcloned into pYLVS to produce pYLVS-

5   PinII. The pYLVS-PinII and pYLTAC747-HPT-MAR-GNA were used to co-

6   transform to NS3529 to form a recombined plasmid. The recombined plasmid

7   was selected on LB medium containing kanamycin and chloramphenicol,

8   purified and re-transferred to DH10B. The integrated plasmid was subjected to

9   I-*Sce*I digestion to cut off the pYLVS backbone, and ligated with the linker S

10   with T4 DNA ligase to form a circular plasmid. After testing for

11   chloramphenicol-sensitivity, a new plasmid named pYLTAC747- HPT-MAR-

12   MAR-GNA-PinII was obtained (Fig. 5 lane 5).

13   The rice genes, RAC22/RCH10 genes (6.4 kb) that were originally

14   cloned to the same plasmid vector, were subcloned into pYLSV to produce

15   pYLSV-RAC22/RCH10. The pYLSV-RAC22/RCH10 and pYLTAC747-HPT-

16   MAR-GNA-PinII were used to co-transform NS3529, and formed a recombined

17   plasmid. The recombined plasmid was selected on an LB medium containing

18   kanamycin and chloramphenicol, purified and re-transferred to DH10B. The

19   integrated plasmid was purified and subjected to PI-*Sce*I digestion to cut off the

20   pYLSV backbone. The digested plasmid was ligated with the oligo-nucleotide

21   linker V with T4 DNA ligase to form a circular plasmid. After testing for

22   chloramphenicol-sensitivity, a new plasmid named pYLTAC747-HPT-MAR-

23   GNA-PinII-RAC22/RCH10 was obtained (Fig. 5 lane 6).

24   The Xa21 gene (9.7 kb) was subcloned into pYLVS to produce

1   pYLVS-Xa21. The pYLVS-Xa21 and pYLTAC747-HPT-MAR-GNA-PinII-

2   RAC22/RCH10 were used to co-transform NS3529, and form a recombined

3   plasmid. The recombined plasmid was selected on LB medium containing

4   kanamycin and chloramphenicol, purified and re-transferred to DH10B. The

5   integrated plasmid was purified and subjected to I-SceI digestion to cut off the

6   pYLVS backbone. The digested plasmid was ligated with the oligo-nucleotide

7   linker S with T4 DNA ligase to form a circular plasmid. After testing for

8   chloramphenicol-sensitivity, a new plasmid named pYLTAC747-HPT-MAR-

9   GNA-PinII-RAC22/RCH10-Xa21 was obtained (Fig. 5 lane 7, note that the

10   Xa21 gene does not have two NotI sites inside).

11   The Bar gene (1.8 kb) was sub-cloned into pYLSV to produce pYLSV-

12   Bar. The pYLSV- Bar and pYLTAC747HPT-MAR-GNA-PinII-

13   RAC22/RCH10-Xa21 were used to co-transform NS3529, and formed a

14   recombined plasmid. The recombined plasmid was selected on LB medium

15   containing kanamycin and chloramphenicol, purified and re-transferred to

16   DH10B. The integrated plasmid was purified and subjected to PI-SceI digestion

17   to cut off the pYLSV backbone. The digested plasmid was ligated with the

18   oligo-nucleotide linker V with T4 DNA ligase to form a circular plasmid. After

19   testing for chloramphenicol-sensitivity, a new plasmid pYLTAC747-HPT-

20   MAR-GNA-PinII- RAC22/RCH10-Bar was obtained (Fig. 5 lane 8).

21   The plasmid pYLVS-MAR previously obtained and pYLTAC747HPT-

22   MAR-GNA- PinII-RAC22/RCH10-Xa21-Bar were used to co- transform *E. coli*

23   NS3529 to form a recombined plasmid. The plasmid was selected on LB

24   medium containing kanamycin and chloramphenicol, purified and re-transferred

27

1   to DH10B. The plasmid was purified and subjected to I-*Sce*I digestion to cut off

2   the pYLVS backbone. The digested plasmid was ligated with the oligo-

3   nucleotide linker S with T4 DNA ligase to form circular plasmid. After testing

4   for chloramphenicol-sensitivity, a new plasmid pYLTAC747- HPT-MAR-

5   GNA-PinII-RAC22/RCH10-Bar-MAR was obtained (Fig. 5 lane 9).

6   The GUS gene flanked by LB and RB (LB/GUS/RB, 3.0 kb) was

7   subcloned into pYLSV to produce pYLSV-LB/GUS/RB. The pYLSV-

8   LB/GUS/RB and pYLTAC747-HPT-MAR-GNA-PinII-RAC22/RCH10-Xa21-

9   Bar-MAR were used to co-transform NS3529, and formed a recombined

10   plasmid. The recombined plasmid was selected on LB medium containing

11   kanamycin and chloramphenicol, purified and re-transferred to DH10B. The

12   integrated plasmid was purified and subjected to PI-*Sce*I digestion to cut off the

13   pYLVS backbone, and ligated with the linker V with T4 DNA ligase to form a

14   circular plasmid. After testing for chloramphenicol-sensitivity, a new plasmid

15   named pYLTAC747-HPT-MAR-GNA-PinII-PAC22/PCH10-Xa21-Bar-MAR-

16   LB/GUS/RB was obtained (Fig. 5 lane 10).

17   A final construct contained ten foreign genes and functional DNA

18   sequences and was re-named pYLTAC747-10G. The structure of the gene

19   between RB and LB was shown in Fig. 6. The figures in blanket were the order

20   of the genes or DNA sequences being inserted to the vector. N denotes *Not*I sites

21   derived from the linker S and linker V or existed in the vector and the Xa21 gene.

22   The figures present between *Not*I sites indicate the fragment length (kb). This

23   example proves that the method disclosed in the present invention is effective for

24   assembly of multiple genes and DNA sequences of different sources in a vector.

1   **Example 4**

2   This example shows the effectiveness of the multi-gene transformation

3   vector for transfer of multiple genes together into rice genome.

4   The plasmid pYLTAC747-10G was transferred to *A. tumefaciens*

5   EHA105 to obtain *Agrobacterium* clone EHA105[pYLTAC747-10G].

6   EHA105[pYLTAC747-10G] was used to transform rice callus tissue.

7   pYLTAC747-10G contains the HPT and Bar genes that can be used for selection

8   of transformants with hygromycin and/or herbicide Basta. Rice embryos were

9   inoculated to a medium to induce calli at 25°C in dark. The induced calli was

10   transferred to subculture medium. The EHA105[pYLTAC747-10G] cells were

11   cultured on YM agar medium at 28°C for 24 hours, followed by culture in 40 ml

12   MB liquid medium containing 100 µmol/L acetosyingone at 28°C until

13   OD_{550}=0.5-1.0. The calli was inoculated with EHA105 [pYLTAC747-10G] for

14   20 minutes, transferred to MB agar medium, and cultured at 25°C for 72 hours in

15   dark. The calli were transferred to a medium containing 50 mg/L hygromycin for

16   selective culture for 4 weeks. After selection, the calli were transferred to a

17   regeneration medium to regenerate plantlets. More than 50 transformed rice

18   plants were obtained.

19   **Example 5**

20   This example was the detection of transgenes from transformed rice

21   plants by molecular hybridization.

22   Genomic DNAs were isolated from the T_0 transgenic rice plants and

23   digested by restriction endonuclease *Hind*III and run onto an agarose gel. After

24   blotting to a hybridization membrane, the transgenes integrated to rice genome

1   were detected using the transgene fragments as probes. As shown in Fig. 7, in

2   most transgenic plants all transgenes present in the same T-DNA region were

3   transferred together into the rice genome. Lane M is a lambda DNA/*Hind* III

4   molecular weight marker. These results demonstrate that the multi-gene vector

5   constructed according to the present invention can effectively transfer multiple

6   genes into plant genomes.

7   Although the invention has been explained in relation to its preferred

8   embodiments, many other possible modifications and variations can be made

9   without departing from the spirit and scope of the invention as hereinafter

10   claimed.

1 <u>**REFERENCES**</u>

2 1. Albert H., Dale E.C., Lee E. and OW D.W. (1995) *Plant J.*,7:649-659.

3 2. Belfort M. & Roberts R. J. (1997) *Nucl. Acids Res.*, 25:3379-3388.

4 3. Chen L., Marmey P., Taylor N. J., et al. (1998) *Nat. Biotechnol.* 16: 1060-

5   1064.

6 4. Daniell H., Dhingra A. (2001) *Current Opinion in Biotechnology.*, 13:136-

7   141.

8 5. Halmilton C. M. (1997) *Gene*, 200:107-116.

9 6. Halpin C., Barakate A., Askaii B.M., et al. (2001). *Plant Mol. Biol.*, 47:295-

10   310.

11 7. Lapierre C., Pollet B., Petit-Conil M., et al. (1999) *Plant Physiol.*, 119:153-

12   163.

13 8. Liu Y. G., Shirano Y., Fukaki H., et al. (1999) *Proc. Natl. Acad. Sci. USA.*,

14   96:6535-6540.

15 9. Ma J. K. Hiatt A., Hein M., et al. (1995) *Science.*, 268:716-719.

16 10. McCormac A. C., Elliott M. C. & Chen D. F. (1999) *Mol. Gen. Genet.*,

17   261:226-235.

18 11. Mcleld M., Craft S., & Broach J.R. (1986) *Mol. Cell. Biol.*, 6:3357-3367.

19 12. Merker P., Muskhelishvili G. (1993) *Cold Spring Harbour Symp. Quart,*

20   *Biol.*, 58:505-513.

21 13. Mostov K. & Lehner T. (1995) *Science.* 268:716-719.

22 14. Nash H.A. (1981) *Ann. Rev. Genet.* 15:143-167.

23 15. Shizuya H., Birren B., et al. (1992) *Proc. Natl. Acad. Sci. USA.*, 89:8794-

24   8797.

1   16. Sternberg N. & Hamilton D. (1981) *J. Mol. Biol.*, 150:467-486.

2   17. Sternberg N. (1990) *Proc.Natl. Acad. Sci. USA*. 87:103-107.

3   18. van Engelen FA, Schouten A, et al. (1994) *Plant Mol Biol.* 26:1701-10.

4   19. Ye X., Al-Babili S., Klöti A., Zhang J., et al. (2000) *Science*, 287:303-305.